Task: gap018 | Last Updated: 2026-03-24 | Kind: gap-analysis | Total Gaps Identified: 8
¶ Repeat Length and Phenotype Correlation (2026)
New studies have refined the relationship between repeat length and clinical phenotype:
- Somatic mosaicism: Blood vs. CSF repeat lengths showing divergence, with longer repeats in CNS correlating with ALS phenotype
- Intergenerational instability: Parent-of-origin effects on repeat expansion magnitude and clinical phenotype
- ** methylation analysis**: DNA methylation patterns at the C9orf72 promoter as phenotypic modifier
Advances in understanding DPR pathology:
- GA toxicology: Poly-GA aggregates impair proteasome function; antibody therapeutics in development
- Phase separation: Liquid-liquid phase separation of DPR proteins and RNA granules in disease pathogenesis
- Strain diversity: Different DPR "strains" with varying aggregation and toxicity properties
Gene therapy and small molecule approaches:
- Antisense oligonucleotides: Multiple ASO candidates targeting C9orf72 transcription show promise in preclinical models
- Small moleculeRAN GAPs: Compounds reducing toxic RNA foci formation
- CRISPR base editing: Allele-specific editing approaches entering preclinical development
Phenotype prediction through biomarkers:
- CSF DPR levels: Differential DPR species in ALS vs. FTD patients
- Neurofilament patterns: pNfH/NfL ratio differing between phenotypes
- TMEM106B genetics: New risk variants modulating phenotype expression
The hexanucleotide repeat expansion in the C9orf72 gene is the most common genetic cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). A striking puzzle in the field is why the same mutation can cause ALS in one family member and FTD in another, even within the same pedigree. This phenotypic divergence represents a major knowledge gap with implications for genetic counseling, clinical trial design, and mechanistic understanding of neurodegeneration.
¶ C9orf72 Genetics and Repeat Expansion
The C9orf72 gene located on chromosome 9p21 encodes a DENN domain protein involved in endosomal trafficking and autophagy. The most common pathogenic mutation is a GGGGCC hexanucleotide repeat expansion in the first intron of the gene:
- Normal: < 30 repeats
- Intermediate: 30-200 repeats (reduced penetrance)
- Pathological: > 200 repeats (fully penetrant)
The expansion leads to three gain-of-toxicity mechanisms:
- Loss of function: Reduced C9orf72 protein expression due to transcriptional silencing
- RNA toxicity: Aberrant binding of transcription factors and RNA-binding proteins to expanded RNA foci
- Dipeptide repeat (DPR) protein toxicity: Non-canonical translation produces toxic DPR proteins (GP, GA, PR, GR, PA)
| Phenotype |
Percentage |
Key Features |
| ALS only |
~50% |
Progressive muscle weakness, bulbar dysfunction, respiratory failure |
| FTD only |
~30% |
Behavioral changes, language dysfunction, executive impairment |
| ALS-FTD |
~20% |
Overlapping symptoms affecting both motor and cognitive domains |
Even within the same family carrying the same repeat expansion, individuals present with dramatically different phenotypes:
- Siblings with identical repeat lengths can develop ALS vs FTD
- Age of onset varies from 35-75 years (mean ~55 years)
- Disease duration ranges from 1-10+ years
- Phenotypic discordance in monozygotic twins reported in multiple families
- Earlier onset in subsequent generations observed in some pedigrees
- May be related to repeat instability during spermatogenesis
- Paternal anticipation appears more common than maternal
Expanded C9orf72 RNA forms nuclear and cytoplasmic foci that sequester essential RNA-binding proteins:
- TDP-43: Primary pathology in both ALS and FTD
- hnRNPs (hnRNPA1, hnRNPA2B1): RNA processing and splicing factors
- Transcription factors: Altered gene expression patterns
This sequestration disrupts normal RNA processing, potentially favoring either motor neuron or frontal lobe vulnerability depending on which protein pools are depleted in specific neuronal populations.
Ribosomal translation of the expanded repeat in all three reading frames produces toxic dipeptide repeat proteins:
| DPR Species |
Abundance |
Primary Cellular Effect |
| Poly-GA |
Most abundant |
Impairs proteostasis, aggresome formation |
| Poly-PR |
Second most |
Interferes with nuclear transport, nucleocytoplasmic trafficking |
| Poly-GP |
Variable |
Less toxic, serves as biomarker for DPR production |
| Poly-GR |
Lower |
Binds RNA, may alter splicing |
| Poly-PA |
Lowest |
Less characterized |
The relative abundance and distribution of different DPRs may determine the clinical phenotype. Poly-GA is more abundant in FTD brains while poly-PR shows greater toxicity in motor neurons.
Both ALS and FTD are characterized by TDP-43 protein aggregates:
- ALS: Motor cortex, spinal cord anterior horns, bulbar nuclei
- FTD: Frontal and temporal cortices, limbic system
- ALS-FTD: Both motor and frontotemporal regions
The pattern of TDP-43 deposition may reflect vulnerability of specific neuronal populations. Whether TDP-43 pathology is primary or secondary to C9orf72 toxicity remains unclear.
Multiple genetic loci modify the ALS-FTD phenotype:
| Gene/Region |
Effect |
Mechanism |
Evidence |
| UNC13A |
Modifies ALS risk/phenotype |
Motor neuron vulnerability |
GWAS, eQTL |
| TMEM106B |
Modifies FTD risk |
Lysosomal function, DPR aggregation |
GWAS, functional studies |
| APOE ε4 |
Increases FTD risk |
Amyloid clearance, neuroinflammation |
Association studies |
| ATXN2 |
Modifies ALS risk |
RNA processing, stress granules |
Repeat expansion intermediate |
| chr9q21-22 |
Phenotype modifier |
Unknown |
Linkage studies |
TMEM106B haplotypes demonstrate the strongest modifier effect:
- Risk haplotype (T) increases FTD risk 2-3x in C9orf72 carriers
- Protective haplotype (A) associated with earlier ALS onset
- May influence DPR aggregation and lysosomal function
- DNA methylation at the C9orf72 promoter correlates with repeat size and age
- Histone modifications may alter toxic RNA foci formation
- X-chromosome inactivation patterns in females may contribute to gender differences
- Smoking: Increases ALS risk, may interact with C9orf72
- Head trauma: Potential FTD risk factor
- Physical activity: Complex relationship with ALS (protective in some studies, risk in others)
- Age: Older age at onset associated with FTD phenotype
Recent studies have advanced our understanding of phenotypic divergence:
- Single-cell RNA sequencing reveals distinct molecular signatures in C9orf72 carriers with different phenotypes, with motor neurons showing enhanced stress response pathways
- Cerebrospinal fluid DPR levels correlate with disease progression but not phenotype, suggesting DPR burden is a general disease marker
- Epigenetic modifications may influence phenotype expression through differential methylation patterns
- iPSC-derived neurons from ALS vs FTD patients show differential vulnerability to DPR toxicity
- Spatial transcriptomics identifies region-specific gene expression changes that may explain phenotypic patterns
- Poly-GA seeding experiments suggest different prion-like propagation patterns in ALS vs FTD
- Primary driver: What is the primary toxic species (RNA foci, DPRs, or loss of function)?
- Modifier mechanism: How do TMEM106B and UNC13A actually modify phenotype?
- TDP-43 initiation: What triggers TDP-43 pathology in specific brain regions?
- Therapeutic target: Which mechanism should be targeted for maximum clinical benefit?
- Biomarkers: Can we develop phenotype-predictive biomarkers?
Recent findings (March 2026) on C9orf72 phenotype divergence:
- Tissue-specific vulnerability: C9orf72 expansions primarily affect motor neurons and frontotemporal circuits, with ALS progression typically occurring over 2-5 years, while FTD progresses differently
- GGGGCC repeat mechanism: Repeats form RNA-driven condensates, including protein-free condensates, via G-quadruplex formation — a mechanism distinct from other repeat disorders
- Genomic instability: Contributes to disease variability, with anticipation and parent-of-origin effects, though controversial in C9orf72
- Sequence interruptions: Modulate repeat stability and phenotype, influencing diagnostic interpretation
- DPR strain diversity: Different dipeptide repeat protein conformations show varying aggregation and toxicity properties, with poly-GA more abundant in FTD brains and poly-PR showing greater motor neuron toxicity
- TMEM106B modifier: Lysosomal pathway modulation by TMEM106B genotype influences C9orf72 disease phenotype expression
- Therapeutic implications: RNA-targeting conjugates for other repeat disorders received FDA Breakthrough Therapy designation, while ASOs targeting C9orf72 failed clinically, suggesting multi-targeted approaches may be required